Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals, Inc. (LBPH)
Company Research
Source: Business Wire
Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 yearsRecently initiated Phase 3 global clinical trial (the DEEp SEA Study) to evaluate bexicaserin in Dravet syndrome for participants ages 2-65 years LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported third quarter 2024 financial results.RECENT UPDATES:In October, announced an agreement for H. Lundbeck A/S (Lundbeck) to acquire Longboard in a strategic dealBexicaserin (LP352), an oral, centrally acting, 5-HT2C superagonist in development for the potential treatment of seizures associated with DEEsInitiated Phase 3 global DEEp SEA Study in Dravet syndrome evaluating participants ages 2-65 yearsPACIFIC open-label ext
Show less
Read more
Impact Snapshot
Event Time:
LBPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LBPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LBPH alerts
High impacting Longboard Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
LBPH
News
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates B, LBPH, ZUO on Behalf of ShareholdersPR Newswire
- Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)Business Wire
- Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]Yahoo! Finance
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RVNC, LBPH, ZUO on Behalf of ShareholdersPR Newswire
- LONGBOARD PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Longboard Pharmaceuticals, Inc. - LBPHBusiness Wire
LBPH
Earnings
- 11/7/24 - Miss
LBPH
Sec Filings
- 11/20/24 - Form SC
- 11/20/24 - Form SC
- 11/19/24 - Form 4
- LBPH's page on the SEC website